All dollar amounts reflected in Canadian dollars unless otherwise stated. Vancouver, British Columbia, August 28, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing...
DOWNLOAD VANCOUVER, BC, July 29, 2025 – Rakovina Therapeutics Inc. (TSXV: RKV) (FSE: 7JO0) (the “Company” or “Rakovina”), a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug discovery, is...
DOWNLOAD Vancouver, British Columbia, August 26, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through Al-powered drug discovery, today announced...
DOWNLOAD VANCOUVER, BC, July 24, 2025 Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company” or “Rakovina”) a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug discovery is pleased to announced...
DOWNLOAD KT-3283, a duel PARP-HDAC inhibitor, to serve as first development program in NanoPalm’s strategic expansion into the oncology field Vancouver, British Columbia & Riyadh, Saudi Arabia August 12, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or...
Be in the know with the Rakovina Therapeutics monthly investor newsletter! Each month you’ll find out what’s going on with the company and be the first to receive news release straight to your inbox.
Recent Comments